Expanded Access Theme Is One Sour Note For Biopharma In “21st Century Cure” Roundtable
This article was originally published in RPM Report
Executive Summary
The Energy & Commerce Committee “21st Century Cures” Process promises to set a pro-innovation tone heading into the next user fee reauthorization cycle. There is one theme, however, that may be perilous for industry moving forward: Expanded Access.